---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-067511"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2025-05-09T23:59:59+00:00"
generated_at: "2026-05-22T01:51:06.309387+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma Q1 net loss $17.5M; Phase 2 interim data expected mid-2025

## Summary
- Phase 2 PYNNACLE interim analysis mid-2025; data for ~50 patients with ≥18 weeks follow-up.
- Cash $165.8M as of March 31, 2025 vs $183.3M Dec 31, 2024; runway to end of 2026.
- Net loss Q1 2025 $17.5M ($15.3M Q1 2024); R&D expenses $17.4M vs $13.2M.
- G&A expenses decreased to $4.1M from $5.0M on reduced headcount and facility spend.
- Rezatapopt discovery paper published in Cancer Discovery.

## SEC filing metadata
- accession: 0000950170-25-067511
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2025-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000095017025067511/0000950170-25-067511-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000095017025067511/pmvp-20250509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-067511
- JSON: https://secwatch.observer/filing/0000950170-25-067511.json
- Plain text: https://secwatch.observer/filing/0000950170-25-067511.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.